Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma

• Main Authors: Nan Zhang (Author), Xu Yang (Author), Mingjian Piao (Author), Ziyu Xun (Author), Yunchao Wang (Author), Cong Ning (Author), Xinmu Zhang (Author), Longhao Zhang (Author), Yanyu Wang (Author), Shanshan Wang (Author), Jiashuo Chao (Author), Zhenhui Lu (Author), Xiaobo Yang (Author), Hanping Wang (Author), Haitao Zhao (Author)
• Format: Book
• Published: BMC, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Systemic therapies using programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors have demonstrated commendable efficacy in some patients with advanced hepatocellular carcinoma (HCC); however, other individuals do not respond favorably. Hence, identifying the biomarkers, t...